| 구분 |
보고서 (영문) |
| 제약/바이오/임상시험 |
Bladder Cancer-Focused CG Oncology Files for IPO |
| At Least Three Oncology 2023 Brand Launches Have Blockbuster Potential |
| Contract Manufacturing: Opportunities and Threats – January 2024 |
| Bio/Pharmaceutical Outsourcing Report, January 2024 |
| Contract Service Agreements – January 2024 |
| January Quarterly Contract Manufacturing Mergers, Acquisitions, and Financing – Q1 2024 |
| Gilead’s Trodelvy Falters as Next Major ADC in Phase III NSCLC Trial |
| Moderna Leads the Development of mRNA Vaccines in Infectious Diseases |
| Cell and Gene Therapies – Top Pharmaceutical Industry Trend to Watch for 2024 |
| FDA Awarded Record Number of Review Designations to CRISPR Drugs in 2023 |
| 질환별 |
Follow-Up Analysis Reinforces Opdivo’s Use in PD-L1 Urothelial Carcinoma Patients |
| Substance Use Disorder Linked with Increased Cardiac Mortality |
| Increased Global Deaths from Fungal Disease Highlights Disease Management Obstacles |
| Enlarged Prostate Decreases Quality of Life in Men |
| 2024 Kicks Off with a Surge in Clinical Trials Tackling Women’s Infertility |
| Could MicroRNAs Offer a New Approach to the Diagnosis of Lupus Nephritis in Systemic Lupus Erythematosus? |
| The US Dominates Ongoing/Planned Trials Researching Skin Cancer |
| 컨퍼런스/심포지엄/학회/기타 |
Merck Is on the Lookout for More Opportunities Within Immunology |
| AstraZeneca Posts Positive Preliminary Results for Imfinzi in TACE-Eligible Hepatocellular Carcinoma |
| Germany’s Ministry of Health Refutes Accusations of Worsening Market Conditions |
